Raloxifene
WikiDoc Resources for Raloxifene |
Articles |
---|
Most recent articles on Raloxifene |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Raloxifene at Clinical Trials.gov Clinical Trials on Raloxifene at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Raloxifene
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Raloxifene Discussion groups on Raloxifene Patient Handouts on Raloxifene Directions to Hospitals Treating Raloxifene Risk calculators and risk factors for Raloxifene
|
Healthcare Provider Resources |
Causes & Risk Factors for Raloxifene |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Synonyms: RAL, Raloxifene Hcl, Raloxifene Hydrochloride, Raloxifeno, Raloxifenum, LY-139481
Brand Names: Evista, Keoxifene
Dosing and Administration
Adult women
PO 60 mg every day.
Adapted from the FDA Package Insert. Template:SIB Template:WH